Oral nanomedicine improves cancer immunotherapy by harnessing gut bacterial metabolite

AI Summary

Researchers have developed a novel oral nanomedicine that uses gut bacterial metabolites to enhance cancer immunotherapy, marking the world's first microbiome-based nanomedicine with significant immune-boosting effects.

A joint research team—led by professor Young Seok Cho from the School of Medicine, alongside professor James J. Moon from the University of Michigan—has developed the world's first oral, microbiome-based nanomedicine. By leveraging natural metabolites produced by gut bacteria, the new drug significantly enhances immune cells' ability to attack cancer cells. The study was published in Nature Nanotechnology.